POPULARITY
Join host Richard L. Lindstrom, MD, as he dives into the world of physician-entrepreneurship in ophthalmology with guests Ashley Brissette, MD, MSc, FRCSC; Ranya Habash, MD; and John A. Hovanesian, MD. Together, they explore the stages of launching a startup as an ophthalmologist—from identifying unmet needs to navigating financial backing and industry partnerships to balancing clinical practice against business ambitions. Learn how these trailblazers are reshaping the future of patient care, overcoming challenges, and pushing the boundaries of innovation in ophthalmology. For more on this topic, check out the May issue of CRST: https://crstoday.com/articles/may-2023.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD. · Welcome to the Eyeluminaries podcast :01 · Review of episode 12 with Richard L. Lindstrom, MD :30 · Preview of episode 13 1:35 · Gil Kliman, MD, introduction 2:36 · History of Silicon Valley Bank 4:25 · Silicon Valley Bank's collapse 6:08 · Guest welcome 8:07 · Was the collapse a surprise? 8:22 · Kliman on major themes of this event being how fast it happened and how unprecedented it was for companies 9:34 · How many ophthalmic companies have been affected, and what are the next steps for these companies? 10:16 · Kliman on the turning point when the FDIC stepped in on Sunday 11:50 · Have you had companies report that they have accessed their funds at Silicon Valley Bank? 12:27 · Kliman on his experience with Silicon Valley Bank 12:45 · What should companies do going forward, and what are you advising companies? 14:17 · Kliman on figuring out a new strategy and the unique issue of 90% of depositors being above the $250,000 FDIC threshold 16:13 · What is the survival rate for small banks now? 17:31 · What do you think the flavor of the room will be at Eyecelerator@ASCRS? 19:20 · Kliman's advice for companies to focus on burn rates 20:35 · The physician's perspective for supporting innovation and small business 21:54 · How strategics can continue to partner with startups using their venture arm 24:04 · Information on the Eyecelerator meeting 25:46 · Wrap up and thank you, Gil 26:16 · Feedback, questions and guest suggestions at eyeluminaries@healio.com 26:45 · Thanks for listening, and preview of episode 14 27:11 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Gil Kliman, MD, is managing partner at InterWest Partners and is co-founder and program director of Eyecelerator. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Kliman is managing partner at InterWest Partners.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology. Welcome to the Eyeluminaries podcast :00 OTF Meeting 01:41 Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04 Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42 The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21 Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24 Best of the year award – Pegcetacoplan 6:49 Near miss award – Beovu (brolucizumab) 8:08 Awful award – Byooviz (ranibizumab-nuna) 8:45 Guest welcome 9:40 Richard L. Lindstrom, MD, introduction 10:31 FDA grants fast track designation for retinitis pigmentosa treatment 10:36 EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14 Amazon launches discount prescription drug service 17:46 Interview with Lindstrom 21:42 What is the biggest innovation in ophthalmology in your career? 22:40 What is coming in the next 10 years? 25:24 What is out there that will get in the way of innovation? 26:54 What advice would you give to residents? 28:35 What advice would you give to entrepreneurs? 30:16 What story can you share about one historical figure in ophthalmology? 31:59 Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14 Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29 Thanks for listening 36:53 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.
Dr Lindstrom has been on the forefront of innovation in ophthalmology for many decades. He brings a wealth of knowledge about staying on the cutting edge of new developments, technology, and techniques in your career. Truly an enlightening conversation and I'm sure that you will learn so much while enjoying it.
In this special Thanksgiving episode of Ophthalmology Off the Grid, host Blake Williamson, MD, MPH, invites his colleagues to join him in expressing their gratitude. Hear from Dr. Williamson; Richard L. Lindstrom, MD; Evan Schoenberg, MD; Iqbal Ike K. Ahmed, MD, FRCSC; and Zaina Al-Mohtaseb, MD, on what has them feeling thankful in these particularly challenging times.
In this special Thanksgiving episode of Ophthalmology Off the Grid, host Blake Williamson, MD, MPH, invites his colleagues to join him in expressing their gratitude. Hear from Dr. Williamson; Richard L. Lindstrom, MD; Evan Schoenberg, MD; Iqbal Ike K. Ahmed, MD, FRCSC; and Zaina Al-Mohtaseb, MD, on what has them feeling thankful in these particularly challenging times.
Richard L. Lindstrom, MD, a long-time supporter of ophthalmology start-ups, looks ahead at the challenges facing physicians and investors as they work to meet the growing demand for ophthalmic treatment in an evolving healthcare industry.